Rare APOA5 mutations-Clinical consequences, metabolic and functional effects. An ENID review

Atherosclerosis

Volumn 194, Issue 2, 2007, Pages 287-292

  Talmud, Philippa J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Apolipoprotein AV; Chylomicronaemia; Rare mutations

Indexed keywords

APOA5 GENE; GENE; GENE MUTATION; GENOTYPE; HUMAN; LIVER; METABOLISM; PHENOTYPE; PLASMA; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOLIPOPROTEINS; APOLIPOPROTEINS A; DISEASE MODELS, ANIMAL; HUMANS; HYPERLIPOPROTEINEMIA TYPE IV; MICE; MICE, KNOCKOUT; PEDIGREE; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

EID: 34249300603     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.12.010     Document Type: Review

References (24)

1. Groenendijk M., Cantor R.M., de Bruin T.W., and Dallinga-Thie G.M. The apoAI-CIII-AIV gene cluster. Atherosclerosis 157 (2001) 1-11
2. Pennacchio L.A., Olivier M., Hubacek J.A., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001) 169-173
3. Schaap F.G., Nierman M.C., Berbee J.F., et al. Evidence for a complex relationship between apoAV and apoCIII in patients with severe hypertriglyceridemia. J Lipid Res 47 (2006) 2333-2339
4. van der Vliet H.N., Sammels M.G., Leegwater A.C., et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 276 (2001) 44512-44520
5. O'Brien P.J., Alborn W.E., Sloan J.H., et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 51 (2005) 351-359
6. Grosskopf I., Baroukh N., Lee S.J., et al. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol 25 (2005) 2573-2579
7. van Dijk K.W., Rensen P.C., Voshol P.J., and Havekes L.M. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?. Curr Opin Lipidol 15 (2004) 239-246
8. Lai C.Q., Parnell L.D., and Ordovas J.M. The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol 16 (2005) 153-166
9. Pennacchio L.A., Olivier M., Hubacek J., et al. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Gen 11 (2002) 3031-3038
10. Olivier M., Wang X., Cole R., et al. Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics 83 (2004) 912-923
11. Schaap F.G., Rensen P.C., Voshol P.J., et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 279 (2004) 27941-27947
12. Merkel M., Loeffler B., Kluger M., et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280 (2005) 21553-21560
13. Chan D.C., Watts G.F., Nguyen M.N., and Barrett P.H. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 Kinetics. Arterioscler Thromb Vasc Biol 26 (2006) 590-596
14. Oliva C.P., Pisciotta L., Li V.G., et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 25 (2004) 411-417
15. Marcais C., Verges B., Charriere S., et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 115 (2005) 2862-2869
16. Oliva C.P., Pisciotta L., Guardamagna O., et al. A novel sequence variant in APOA5 gene found in patients with severe hypertriglyceridemia. Atherosclerosis 188 (2006) 215-217
17. Calandra S., Oliva C.P., Tarugi P., and Bertolini S. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol 17 (2006) 122-127
18. Lookene A., Beckstead J.A., Nilsson S., Olivecrona G., and Ryan R.O. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem 280 (2005) 25383-25387
19. Merkel M., and Heeren J. Give me A5 for lipoprotein hydrolysis!. J Clin Invest 115 (2005) 2694-2696
20. Henneman P., Schaap F.G., Havekes L.M., et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis (2006)
21. Talmud P.J., Cooper J.A., Hattori H., Miller I.P., Miller G.J., and Humphries SE. APOA5 genotype, plasma apolipoprotein AV and triglyceride levels and the prospective risk of type 2 diabetes: results from the Northwick Park Heart Study II. Diabetalogia 49 (2006) 2337-2340
22. Talmud P.J., Palmen J., Putt W., Lins L., and Humphries S.E. Determination of the functionality of common APOA5 polmorphisms. J Biol Chem 280 (2005) 28215-28220
23. Talmud P.J., Hawe E., Martin S., et al. Relative contribution of variation within the APOC3-A4-A5 gene cluster in determining plasma triglycerides. Hum Mol Gen 11 (2002) 3039-3046
24. Nilsson S.K., Lookene A., Beckstead J.A., et al. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Athereosclerosis 7 (2006) 514